NASDAQ:DMAC DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis $4.06 +0.01 (+0.25%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.06 0.00 (-0.12%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About DiaMedica Therapeutics Stock (NASDAQ:DMAC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DiaMedica Therapeutics alerts:Sign Up Key Stats Today's Range$4.00▼$4.2350-Day Range$3.38▼$5.2452-Week Range$2.14▼$6.82Volume80,803 shsAverage Volume80,634 shsMarket Capitalization$174.10 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More… DiaMedica Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreDMAC MarketRank™: DiaMedica Therapeutics scored higher than 30% of companies evaluated by MarketBeat, and ranked 785th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about DiaMedica Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DiaMedica Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.45% of the outstanding shares of DiaMedica Therapeutics have been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in DiaMedica Therapeutics has recently increased by 66.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.45% of the outstanding shares of DiaMedica Therapeutics have been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in DiaMedica Therapeutics has recently increased by 66.86%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.77 News SentimentDiaMedica Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for DiaMedica Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.12% of the stock of DiaMedica Therapeutics is held by institutions.Read more about DiaMedica Therapeutics' insider trading history. Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DMAC Stock News HeadlinesEquities Analysts Offer Predictions for DMAC FY2025 EarningsMay 20, 2025 | americanbankingnews.comDiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of PreeclampsiaMay 20, 2025 | finance.yahoo.comBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 24, 2025 | Crypto 101 Media (Ad)Equities Analysts Offer Predictions for DMAC FY2029 EarningsMay 18, 2025 | americanbankingnews.comEarnings call transcript: DiaMedica Therapeutics Q1 2025 earnings beat expectationsMay 15, 2025 | investing.comDiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comDiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ...May 15, 2025 | finance.yahoo.comDiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025May 14, 2025 | businesswire.comSee More Headlines DMAC Stock Analysis - Frequently Asked Questions How have DMAC shares performed this year? DiaMedica Therapeutics' stock was trading at $5.43 on January 1st, 2025. Since then, DMAC shares have decreased by 25.2% and is now trading at $4.06. View the best growth stocks for 2025 here. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics Inc. (NASDAQ:DMAC) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). Read the conference call transcript. When did DiaMedica Therapeutics IPO? DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. Who are DiaMedica Therapeutics' major shareholders? Top institutional shareholders of DiaMedica Therapeutics include First Manhattan CO. LLC. (1.42%), Royal Bank of Canada (0.36%), Goldman Sachs Group Inc. (0.28%) and Jane Street Group LLC (0.23%). Insiders that own company stock include Koch Thomas Von, David J Wambeke, Randall Michael Giuffre, Dietrich John Pauls and Scott Kellen. View institutional ownership trends. How do I buy shares of DiaMedica Therapeutics? Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/13/2025Today5/24/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DMAC CIK1401040 Webwww.diamedica.com Phone(763) 496-5454FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+97.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.67% Return on Assets-40.81% Debt Debt-to-Equity RatioN/A Current Ratio11.81 Quick Ratio11.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book3.01Miscellaneous Outstanding Shares42,883,000Free Float39,682,000Market Cap$174.10 million OptionableOptionable Beta1.29 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:DMAC) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Hidden Energy Source Backed by Billionaires Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.